Outlining a Rationale-Based Approach for Combining ADCs With Immune Checkpoint Inhibitors

• Exploring ongoing development and promise of ADC–immune checkpoint inhibitor combinations therapies
• Detailing rationale for ADC combination therapy approaches
• Summarising the potential of ADC–checkpoint inhibitor combinations to boost immune response

Speakers:

Christian Rohlff

Chief Executive Officer

Oxford BioTherapeutics